ENGLEWOOD, Colo., Aug. 6, 2018 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference
call Tuesday, August 7th at
4:30 pm EDT to update the preparation
of the Biologics License Application (BLA) for Ampion™.
Participants are invited to dial in using the instructions as
follows:
Investor call information:
U.S./Canada toll-free number:
800-667-5617
U.S. Local number: +1 334-323-0505
Participant Passcode: 7652532
A replay of Tuesday's conference call will be posted on Ampio's
website within 24 hours. Link posted below.
https://ampiopharma.com/investors/presentations-media/
About Ampio Pharmaceuticals
Ampio Pharmaceuticals,
Inc. is a development stage biopharmaceutical company primarily
focused on the development of therapies to treat prevalent
inflammatory conditions for which there are limited treatment
options. We are developing compounds that decrease inflammation by
(i) inhibiting specific pro-inflammatory compounds by affecting
specific pathways at the protein expression and at the
transcription level; (ii) activating specific phosphatase or
depletion of the available phosphate needed for the inflammation
process; and (iii) decreasing vascular permeability.
Forward-Looking Statements
Ampio's
statements in this press release that are not historical fact, and
that relate to future plans or events, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements can be identified by
the use of words such as "believe," "expect," "plan," "anticipate,"
and similar expressions. These forward-looking statements include
statements regarding Ampio's expectations with respect to Ampion™,
as well as those associated with clinical trials, regulatory
approvals, the ability of Ampio to enter into partnering
arrangements, the Biological License Application (BLA) and
decisions and changes in business conditions and similar events,
all of which are inherently subject to various risks and
uncertainties. The risks and uncertainties involved include
those detailed from time to time in Ampio's filings with the
Securities and Exchange Commission, including without limitation,
under Ampio's Annual Report on Form 10-K and other documents filed
with the Securities and Exchange Commission. Ampio undertakes no
obligation to revise or update these forward-looking statements,
whether as a result of new information, future events or
otherwise.
Company Contact
Tom
Chilcott
Chief Financial Officer
Phone: (720) 437-6500
View original content with
multimedia:http://www.prnewswire.com/news-releases/ampio-hosting-conference-call-tuesday-august-7-430-pm-edt-to-update-the-preparation-of-the-biologics-license-application-bla-for-ampion-300692225.html
SOURCE Ampio Pharmaceuticals, Inc.